Faron keeps it in the family with new CEO

Finland-based Faron Pharmaceuticals (AIM: FARN), a biopharma reprogramming myeloid cells to activate anti-tumor immunity in hematological and solid tumor microenvironments, has announced that its chief executive Markku Jalkanen is to retire.

Faron’s lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through targeting myeloid cell function. It is being investigated in Phase I/II trials as a potential therapy for patients with hematological cancers in combination with other standard treatments and as a monotherapy in last line solid cancers.

Dr Jalkanen, who turns 70 later in 2024, has recently told the board of directors of his wish to retire from his position as the company’s chief executive, while continuing in his role as board member.